New health policy research topped CHIR’s list of beach reads this July. For the latest monthly research roundup, we reviewed studies on marketplace enrollees’ denied claims, how marketplace coverage has benefitted small business and self-employed workers, and out-of-pocket spending on insulin.
As Congress considers a variety of proposals to address prescription drug prices, there is a growing trend of states capping the out of pocket costs for insulin. CHIR’s Megan Houston considers the impact of insulin copay caps and how states are limited in their efforts to tackle prescription drug prices.
In a report released this week by the National Alliance for Mental Illness (NAMI), Georgetown researchers Dania Palanker, JoAnn Volk and Kevin Lucia document the many ways that individual market plans available before the Affordable Care Act (ACA) fell far short of providing adequate, affordable coverage for people with mental illness and substance use disorders.
Lowering the cost of prescription medication has broad support over the political spectrum and there were many campaign promises to reduce prices. But to date, there’s been little federal action. States, however, are taking the lead with policies designed to protect consumers with chronic conditions from high out-of-pocket costs associated with expensive specialty drugs. A new CHIR brief details the findings from a 50-state survey of such policies and observations from supplementary interviews with state regulators, insurance company representatives and consumer advocates.
The opinions expressed here are solely those of the individual blog post authors and do not represent the views of Georgetown University, the Center on Health Insurance Reforms, any organization that the author is affiliated with, or the opinions of any other author who publishes on this blog.
